Latest News

States are rationing HIV medications through prior auth and formulary cuts to solve ADAP budget crises — a strategy that costs more, drives resistance, and concentrates harm on the most vulnerable.

ADAPs achieve 87% viral suppression but face funding crisis as multiple policies erode 340B rebates.

340B program drifted from patient benefit; federal reform needed for transparency and accountability.

Senate HELP Committee hearing reveals how 340B drug program expansion reflects hospital business strategy rather than patient benefit.

Congressional Budget Office confirms 340B program expansion driven by hospital exploitation rather than pharmaceutical price inflation.

Pugh reflects on 340B policy and patient advocacy in ensuring equitable medication access.

2024 federal healthcare policy priorities: 340B reform, PBM oversight, and telehealth.

CANN outlines organizational growth and 2024 policy priorities including state-level advocacy.

PDABs and upper-payment limits risk restricting medication access despite affordability intentions.

$100 billion 340B program lacks patient accountability; reform needed for charitable care obligations.

CMS's $9B remedy to hospitals after SCOTUS 340B ruling lacks enforcement of charitable care requirements.

Introduction to PDABs: structure, function, and importance for patient medication access.

340B reform must prioritize patients: charity care obligations and medical debt reduction.

Hospital price transparency and 340B lack accountability while patients face medical debt.

Tennessee rejects $8.3M in federal HIV prevention funding, threatening surveillance and care programs.

ADAP Fireside Chat addresses counterfeit medications, 340B reform, and public health workforce sustainability.

S.4395 would divert Ryan White resources from PLWHA to PrEP, threatening the safety net for vulnerable populations.

Pharmaceutical industry changes to 340B implementation impact pricing and accessibility for covered entities.

CANN announces 2022 organizational changes including rebranding and launching the 340B Action Center.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.